Needham & Company Reiterates Buy Rating on Pacira Pharmaceuticals (PCRX)
Tweet Send to a Friend
Needham & Company analyst Serge Belanger reiterated a Buy rating and $84.00 price target on Pacira Pharmaceuticals (NASDAQ: PCRX)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


